CEO, Hit Discovery Constance (HDC GmbH)
Horst Flotow is a biochemist with many years of experience working in the pharmaceutical industry. After obtaining his Ph.D. from Flinders University of South Australia he carried out Post-Doctoral Research at IUPUI Medical School (Indiana University, USA) and the Friedrich Miescher Institute in Basel, Switzerland.
In 1993 he joined the pharmaceutical industry at the Inflammation Biology department at Roche in the UK, working with protein kinases involved in T-cell signal transduction. Moving to Singapore in 1999, he joined the Centre for Natural Product Research, which then became MerLion Pharmaceuticals. As a Director of High Throughput screening, he was involved in developing and running high throughput screening assays for drug discovery in a variety of therapeutic areas. Following a brief stint as a Research consultant working for Lilly Systems Biology (LSB) he moved to the Experimental Therapeutics Centre when it was established in 2007 as the founding Group Leader for the HTS group and the Head of the Singapore Screening Centre. In 2015 he moved to Germany to take up a position as the CEO of Hit Discovery Constance.